PROCR and ischemia: Additional new genetics (Table 3) may further improve thromboregulation (e.g., tissue factor pathway inhibitor [TFPI], endothelial protein C receptor [EPCR], CD39) or reduce inflammation (HO-1, TNFRI-Fc, A20, CD39) and ischemia–reperfusion injury (CD39, HO-1) [91,92].